The Role of Combination Biologic Therapy in the Immunotherapeutic Approach to the Treatment of Renal Cell Carcinoma

摘要: Renal cell carcinoma (RCC) is the most common malignancy of kidney accounting for approximately 3% all adult cancers. The tumor more among urban dwellers and males, occurs primarily in fifth to seventh decades life. Overt symptoms accompanying RCC are often associated with advanced local or distant disease. Approximately two-thirds locally confined renal tumors found incidentally (1). Surgical extirpation cornerstone therapy localized RCC. In spite years research many clinical trials, management metastatic disease remains undefined.